T cell sub-population profiling studies on days 14 and 21 were analyzed using CD3-PC7 (Beckman Coulter, 6607100), CD4-APC-A700 (Beckman Coulter, B10824), CD8-PC5.5 (Beckman Coulter, B21205), EGFR-A488 (R&D Systems, FAB10951G), CD45RA-ECD (Beckman Coulter, IM2711U), CD45RO-PE (Miltenyi Biotech,130-113-559), CD27-APC-A750 (Beckman Coulter, B12701), and CD62L-APC (Miltenyi Biotech, 130-113-617) antibodies by Cytoflex Flow Cytometer analysis. Exhaustion profiling studies on days 14 and 21 were analyzed using CD3-PC7 (Beckman Coulter, 6607100), CD4-APC-A700 (Beckman Coulter, B10824), CD8-PC5.5 (Beckman Coulter, B21205), EGFR-A488 (R&D Systems, FAB10951G), CD279 (PD1)-PE (Miltenyi Biotech, 130-117-384), CD366 (TIM3)—APC (Invitrogen, Waltham, MA, USA, 17-3109-42), and CD223 (LAG-3)—APC-eFluor 780 (Invitrogen, 47-2239-42) antibodies by Cytoflex Flow Cytometer analysis.
Egfr a488
Manufactured by R&D Systems
Sourced in United States
EGFR-A488 is a fluorescently-labeled anti-EGFR antibody. It is designed for flow cytometry analysis of EGFR expression on cells.
Automatically generated - may contain errors
Lab products found in correlation
Cd3 pc7, by Beckman Coulter (2 mentions)
Cd4 apc a700, by Beckman Coulter (2 mentions)
Cd8 pc5, by Beckman Coulter (2 mentions)
Cd25 apc, by Miltenyi Biotec (1 mentions)
Tc20 automated cell counter, by Bio-Rad (1 mentions)
Trypan blue, by Sartorius (1 mentions)
Cd19 ecd, by Beckman Coulter (1 mentions)
Cd45ra ecd, by Beckman Coulter (1 mentions)
Cd45ro pe, by Miltenyi Biotec (1 mentions)
Cd279 pd1 pe, by Miltenyi Biotec (1 mentions)
Cd62l apc, by Miltenyi Biotec (1 mentions)
2 protocols using egfr a488
1
T cell Profiling and Exhaustion Analysis
2
In Vitro Assessment of CAR-T Cell Efficacy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In vitro studies with CAR-T cells (CD19-CD28z and CD19-BBz) were performed for the assessment of efficacy and cytotoxic capacity. For that purpose, anti-CD19-expressing CAR-T cells and CD19-expressing RAJI cells were cultured for 24 h, 7 days, and 14 days (CAR-T: RAJI; 1:1, 5:1, 10:1). Anti-cancer profiling studies on days 14 and 21 were analyzed using CD3-PC7 (Beckman Coulter, 6607100), CD4-APC-A700 (Beckman Coulter, B10824), CD8-PC5.5 (Beckman Coulter, B21205), EGFR-A488 (R&D Systems, FAB10951G), CD19-ECD (Beckman Coulter, A07770), CD25-APC (Miltenyi Biotech, 130-113-284), and CD107a (LAMP-1) -PE (Miltenyi Biotech, 130-111-621) by Cytoflex Flow Cytometer analysis. In the co-culture experiments, the death of CD19+ RAJI cells after 48 h and the CD25 activation (IL2RA, IL-2 receptor alpha chain) and CD107a (marker for degranulation of lymphocytes) cytotoxic de-granulation biomarkers of CAR-T cells and control T cells in CD3+ T cells were analyzed by flow cytometry. Survival analysis of CAR-T cells was performed to control the cell viability of RAJI cells and CAR-T cells. Trypan blue (Biological Industries, #03-102-1B) was applied to identify and count surviving cells. Cell counting and viability analysis were performed with the BIO-RAD TC20 Automated Cell Counter.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!